Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Spina Bifida
NEJM 387:444-450, Iskandar, B.J. & Finnell, R.H., 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Clinicopathologic Conference, Encephalitis due to Behcets Disease
NEJM 387:925-933, Case 27-2022, 2022
Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022
Oral Contraceptives, Hormone Replacement Therapy, and Stroke Risk
Stroke 53:3107-3115, Johansson, T.et al, 2022
Dura Mater Thickening and Enhancement in Anti-NMDAR Encephalitis
Neurol 99:628-629, Xia, C. & Chen, H.S., 2022
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Thymoma and Autoimmune Encephalitis
Neuroimmunol Neuroinflamm 8:e1053, Guasp,M.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
The SANAD II Study of the Effectiveness and Cost-Effectiveness of Valproate Versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial
Lancet 397:1375-1386, Marson, A.,et al, 2021
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Cerebral Microbleeds
Stroke 52:2347-2355, Graff-Radford, J.,et al, 2021
Initial Management of Seizure in Adults
NEJM 385:251-263, Smith, P.E.M., 2021
A 68-Year-Old Man with Proximal Weakness and Seizures
Neurol 97:e423-e428, Chen, T., 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Area Postrema Syndrome as the Initial Presentation of Alexander Disease
Neurol 97:548-549, Renaldo, F.,et al, 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Caudal Epidural Steroid Injections in the Setting of Remaining on Antithrombotics: A Retrospective Study
Pain Physician 24:e821-e828, Simon,J.I.,et al, 2021
Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis
Front Immunol 12:691536, Ruiz-Garcia,R.,et al, 2021
Case Report: Anti-NMDA Receptor Encephalitis with Bilateral Hearing Loss as the Initial Symptom
Front Neurol doi:10.3389/FNEUR.2021.648911, Cheng,H.,et al, 2021
Anti-NMDAR Encephalitis Presenting as Stroke-Like Episodes in Children: A Case Series from a Tertiary Care Referral Centre from Southern India
J Pediatr Neurosci 16:194-198, Gowda,V.K.,et al, 2021
Antiplatelet and Anticoagulant Risk for Select Spine Interventions:A Retrospective Cohort
Pain Med 21:910-917, Ehsanian,R.,et al, 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
Palatal Myoclonus, Abnormal Eye Movements, and Olivary Hypertrophy in GAD65-Related Disorder
Neurol 94:273-275, Macaron, G.,et al, 2020
A Rare Presentation of Whipple Disease
Neurol 94:e758-e761, Koek, A.T.,et al, 2020
Use of Dual Antiplatelet Therapy Following Ischemic Stroke
Stroke 51:e78-e80, Dong, J.,et al, 2020
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke 51:1616-1619, Beharry, J.,et al, 2020
Anti-NMDAR Encephalitis with Overlapping Demyelinating Syndrome
Neurol 94:e1866-e1869, Kim, H.W., et al, 2020
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Out-of-Hospital Tranexamic Acid for Traumatic Brain Injury
JAMA 324:946-947, Cone, D.C.,et al, 2020
An Adolescent Girl Presenting with Worsening Vertigo, Headache, and Ataxia
Neurol 95:e1760-e1763, Brigham, E.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Spasms and Myoclonus in a Young Woman with Hashimoto Thyroiditis
JAMA Neurol 77:650-651, Shen, D.,et al, 2020
Transient Ischemic Attack
NEJM 382:1933-1941, Amarenco, P., 2020
Relapse of Severe Neurosarcoidosis with Switch from Originator Infliximab to Biosimilar
Neurol 94:991-993, Kidd, D.P.,et al, 2020
Cavernous Sinus Thrombosis
WebMD 2020, , 2020
Choosing Anticonvulsant Medications to Manage Status Epilepticus
NEJM 382:2569-2572, Wu, K., 2020
Paraneoplastic Encephalomyelitis with Glutamic Acid Decarboxylase Antibodies Presenting as Longitudinal Pyramidal Tract Hyperintensity
JAMA Neurol 77:899-900, Miralles, C.,et al, 2020
Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020
Antiplatelet Treatment to Prevent Early Recurrent Stroke
NEJM 383:276-278, Rothwell, P.M., 2020
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled Trial
Lancet 394:1713-1723,1687, The CRASH-3 trial collaborators, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
NEJM 381:2103-2113,2171, Kapur, J.,et al, 2019